ConductScience.org, home

Paper40177643

Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality.

Twomey JD and 2 others. Antib Ther, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality. Papers, record 40177643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40177643

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality.
PubMed
Journal
Antib Ther
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.53, provisional
iCite
Revised in PubMed
2026-01-22
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Twomey JDJulianne D
2George SSasha
3Zhang BBaolinhttps://orcid.org/0000-0002-7859-0843

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References117

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136776883Factors affecting IgG4-mediated complement activation.Front Immunol2023https://conductscience.org/library/papers/36776883PubMed
236726033The therapeutic age of the neonatal Fc receptor.Nat Rev Immunol2023https://conductscience.org/library/papers/36726033PubMed
326497511Mouse and human FcR effector functions.Immunol Rev2015https://conductscience.org/library/papers/26497511PubMed
437489366Detection of Antibody-Dependent Cell-Mediated Cytotoxicity-Supporting Antibodies by NK-92-CD16A Cell Externalization of CD107a: Recognition of Antibody Afucosylation and Assay Optimization.Antibodies (Basel)2023https://conductscience.org/library/papers/37489366PubMed
522531445Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay.MAbs2012https://conductscience.org/library/papers/22531445PubMed
631019955NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.Ann Transl Med2019https://conductscience.org/library/papers/31019955PubMed
715153544
A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function.
J Immunol2004https://conductscience.org/library/papers/15153544PubMed
837764916In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG.Pathogens2023https://conductscience.org/library/papers/37764916PubMed
933440654
ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor.
Cancers (Basel)2021https://conductscience.org/library/papers/33440654PubMed
1024487381Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy.J Neurol Neurosurg Psychiatry2014https://conductscience.org/library/papers/24487381PubMed
1135814459Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies.Front Oncol2022https://conductscience.org/library/papers/35814459PubMed
1210512162Functional CD32 molecules on human NK cells.Leuk Lymphoma1999https://conductscience.org/library/papers/10512162PubMed
1310742152Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med2000https://conductscience.org/library/papers/10742152PubMed
1435332252Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction.Commun Biol2022https://conductscience.org/library/papers/35332252PubMed
1539051331NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for FCGR3.Antibodies (Basel)2024https://conductscience.org/library/papers/39051331PubMed
1617875730Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.Cancer Res2007https://conductscience.org/library/papers/17875730PubMed
1731343409FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding.Elife2019https://conductscience.org/library/papers/31343409PubMed
1828605680Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies.J Pharm Biomed Anal2017https://conductscience.org/library/papers/28605680PubMed
1916115811FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling.Hum Mol Genet2005https://conductscience.org/library/papers/16115811PubMed
2019164213Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.J Clin Oncol2009https://conductscience.org/library/papers/19164213PubMed

See all 117 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42614611Post-Translational Modification-Driven Metabolic Reprogramming Shapes Melanoma Progression and Immune Microenvironment.Clin Cosmet Investig Dermatol2026https://conductscience.org/library/papers/42614611PubMed
42086871A Cell-Based Reporter Gene Assay for TNF-α Neutralization: Analytical Qualification and Application to Adalimumab and Its Biosimilars.Pharm Res2026https://conductscience.org/library/papers/42086871PubMed
41992203FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy.Cancer Cell Int2026https://conductscience.org/library/papers/41992203PubMed
41577853Glycan Profiles of FDA-Approved Therapeutic Antibodies: Insights from Regulatory Submissions.AAPS J2026https://conductscience.org/library/papers/41577853PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FCGR1A2209PubTator's text mininghttps://conductscience.org/library/genes/2209

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40177643

GET https://conductscience.org/api/papers/v1/40177643/references?page=2